Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maoto (TJ-27) is a traditional Japanese Kampo medicine composed of four botanical extracts: Ephedra Herb, Apricot Kernel, Cinnamon Bark, and Glycyrrhiza Root. Developed and manufactured by Tsumura & Co., it is primarily used for the treatment of influenza and the common cold, particularly in the early stages characterized by fever, chills, and joint pain. The extract's mechanism of action involves multiple components, including ephedrine and pseudoephedrine, which act as sympathomimetics, and various flavonoids and glycosides that exhibit anti-inflammatory and antiviral properties. Clinical studies have suggested that Maoto may be as effective as neuraminidase inhibitors like oseltamivir in reducing the duration of fever in influenza patients by modulating the host immune response and potentially inhibiting viral replication. In Japan, it is regulated as a pharmaceutical product and is frequently prescribed for respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maoto extract.